



Polymer Factory Joins LIMMIC to Develop Universal Calibration Standards for Multidimensional Mass Spectrometry

The German innovation project targets the reproducibility gap that keeps ion-mobility and imaging mass spectrometry data from being compared reliably across instruments and laboratories.

Polymer Factory has joined LIMMIC, a German innovation project developing a universal standard for calibrating multidimensional mass spectrometry data. Polymer Factory will develop the polymer-based reference standards at its core: the common benchmark needed to make LC-IMS-MS (Liquid Chromatography-Ion Mobility-Mass Spectrometry) and MS Imaging (MSI) measurements comparable across instruments and laboratories, a persistent barrier in metabolomics, lipidomics and related fields.

In the project, Polymer Factory provides the calibration standards, mzio builds the calibration software and integrates it into the open-source MZmine platform, and CeMOS develops specialized workflows for oxidized lipids.

The opportunity is substantial. The global mass spectrometry imaging market was valued at around USD 4.1 billion in 2024 and is projected to reach USD 7.4 billion by 2034 (Market.us), within a broader mass spectrometry market worth more than USD 7 billion, yet reliable cross-platform calibration remains an unmet need.

"Ion mobility and imaging mass spectrometry are a large and fast-growing field, and the value of that data only compounds when results can be compared across instruments and laboratories," says Mats Wallner, CEO of Polymer Factory. "That common reference is exactly what we build, and LIMMIC lets us develop and validate our SpheriCal® standards for these multidimensional workflows."

LIMMIC is partially funded by the German Federal Ministry for Economic Affairs and Energy (BMWE).

For more information, please contact:

Mats Wallner, CEO

Phone: +46 (0) 70 951 95 06

E-mail: mats.wallner@polymerfactory.com

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company's dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company's vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company's dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.